Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has released a corporate update video featuring their newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video, released on April 22, 2025, is available on the company's website under the Investors section's Presentations page at www.akaritx.com.
Akari Therapeutics (NASDAQ: AKTX) reported its 2024 financial results and corporate updates, marking a transformational year following its merger with Peak Bio Inc. The company is advancing next-generation precision bi-functional Antibody Drug Conjugates (ADCs) for cancer treatment.
Their lead program, AKTX-101, targets solid tumors with a novel spliceosome inhibitor payload, showing superior activity and better tolerability in preclinical models. The company reported a net loss of $21.6 million for 2024, compared to $16.8 million in 2023, with research and development expenses of $7.0 million.
With approximately $2.6 million cash as of December 2024, plus $6.6 million from a March 2025 private placement, Akari expects to fund operations into September 2025. The company appointed Abizer Gaslightwala as new CEO effective April 21, 2025, and is seeking licensing/strategic partners for AKTX-101.
Akari Therapeutics (NASDAQ: AKTX) has appointed Abizer Gaslightwala as President and CEO, effective April 21, 2025. Gaslightwala brings 25 years of biotechnology and pharmaceutical industry experience, most recently serving as SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, where he managed a $1B product portfolio.
The current President and CEO, Dr. Samir Patel, will remain on the Company's Board of Directors. During his 12-month tenure, Dr. Patel oversaw the successful merger of Peak Bio with Akari, transforming it into a targeted oncology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment.
Gaslightwala's extensive experience includes executive leadership roles at Amgen, Pfizer, and Johnson & Johnson, where he worked with major brands such as Kyprolis®, Vectibix®, and ELIQUIS®. He holds degrees from Cornell University and MIT, including an MBA from MIT Sloan School of Management.
Akari Therapeutics (Nasdaq: AKTX) has announced a private placement offering expected to raise $7.6 million in gross proceeds, with strong support from existing shareholders and board members. The financing includes the issuance of 6,637,626 unregistered American Depository Shares (ADSs) priced at $0.87 per ADS, along with Series A and B Warrants.
The deal structure includes the conversion of an existing $1 million convertible note by Board Chairman Dr. Huh, with expected cash proceeds of $6.6 million before fees. The warrants will have an exercise price of $0.87 per ADS, with Series A and B having terms of one and five years respectively.
Funds will be allocated towards the company's spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. Paulson Investment Company serves as placement agent, with closing expected around March 5, 2025.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference.
During the event, CEO Dr. Samir Patel presented the top five reasons why investors and industry colleagues should focus on Akari in 2025. The presentation is now available for viewing online through the company's website and the conference platform.
Akari Therapeutics (NASDAQ: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has announced its participation in the Webull Corporate Connect Service (CCS) platform. This initiative aims to enhance shareholder communication and transparency by providing an additional channel for distributing corporate updates, including company news, earnings reports, product developments, and presentations.
Through the Webull CCS platform, AKTX will maintain direct communication with investors and release timely notifications about corporate developments. The company views this as a strategic addition to their existing corporate social channels and investor relations program, designed to build market awareness and increase visibility among investors.
Akari Therapeutics (NASDAQ: AKTX) has announced two key leadership appointments. Samir R. Patel, M.D., who has served as interim CEO since May 2024, has been appointed permanent Chief Executive Officer effective December 16, 2024. Additionally, Abizer Gaslightwala, a biotechnology industry veteran with over 25 years of experience, has joined the Board of Directors, while Michael Grissinger has resigned.
Dr. Patel highlighted the company's recent merger with Peak Bio and emphasized their focus on streamlining operations and executing their ADC platform strategy. Gaslightwala brings extensive experience from his current role as Senior Vice President and Franchise Head for Oncology at Jazz Pharmaceuticals, where he manages a $1B portfolio including products like ZIIHERA®, ZEPZELCA®, and RYLAZE®.
Akari Therapeutics (Nasdaq: AKTX) has appointed Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck, who previously served as Akari's CFO from 2019 to June 2023, brings over 20 years of biotechnology industry experience. During his previous tenure at Akari, he successfully raised over $50 million. Before rejoining Akari, he served as CFO at Aspira Women's Health. His extensive experience includes roles as Chief Commercial and Strategy Officer at Promethera Biosciences and Co-CEO at Cytonet. The appointment aims to strengthen the company's leadership team as it focuses on advancing its first-in-class ADC platform.
Akari Therapeutics (NASDAQ: AKTX) has successfully resolved its shareholders equity deficiency issue and regained full compliance with Nasdaq listing requirements. The company received written confirmation from Nasdaq's Listing Qualifications Staff that its deficiency under Listing Rule 5550(b) has been cured. As a result, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21 has been cancelled, and AKTX will continue trading on the Nasdaq Capital Market.
Akari Therapeutics announces the completion of its merger with Peak Bio, creating a biotechnology company focused on developing Antibody Drug Conjugates and therapies for autoimmune and inflammatory diseases. The merger includes a $3.2m PIPE financing and a $50m term sheet for an Equity Line of Credit. The company sold 1,713,402 unregistered American Depository Shares at $1.70 per unit (non-insiders) and $2.385 (insiders), along with Series C Warrants. The warrants have a 3-year term and an exercise price of $2.26 per ADS. The ELOC with White Lion Capital provides the right to sell up to $50m of newly issued ADSs over 3 years.